An ongoing dialogue on HIV/AIDS, infectious diseases,
October 10th, 2022
Molnupiravir Results in PANORAMIC Study — It’s Not All Bad News
Last week, the large PANORAMIC trial of COVID-19 treatment in outpatients with mild-moderate disease appeared in a pre-print. This large (25,783 participants!) randomized, open-label study compared molnupiravir vs. usual care in adults 50 or older, or having comorbidities known to make severe disease more likely. The results? Molnupiravir vs standard of care for outpts with Covid19. No […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- How Serious Is Artemisinin Partial Resistance in African Malaria Parasites?
- Observations from ID and Beyond: Who's Going to Get Lenacapavir for HIV Prevention?
- Can We Shorten the Duration of Antibiotic Treatment for Bacteremia?
- Rifampin and Gentamicin for Staphylococcal Prosthetic Valve Endocarditis: Strictly Necessary?
- Gauging Risk for Liver Cancer: Hepatitis B Viral Load Might Be a Clue